Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
Aurore CarrotStéphane OudardOlivier ColombanKarim FizaziDenis MailletA Oliver SartorGilles FreyerBenoit YouPublished in: JCO clinical cancer informatics (2024)
This external validation study confirmed previous results about modeled PSA longitudinal kinetics prognostic value regarding PFS/OS in patients with mCRPC treated with taxanes. PSA.KELIM could be used to identify a subpopulation with poor prognosis, who may benefit from treatment intensification.